Cytokine influence killing fresh chronic lymphocytic leukemia cells human leukocytes feasibility monoclonal antibody MoAb interferon-gamma IFN-gamma treatment chronic lymphocytic leukemia CLL vitro tumor lysis model fresh CLL cells different patients targets distinct normal human leukocyte effector subsets neutrophils peripheral blood mononuclear cells PBMCs antigen expression expression CLL-associated antigens CLL cells neutrophils IFN-gamma absence Neutrophil cytotoxicity ADCC absence IFN-gamma weak inconsistent IFN-gamma exposure MoAb-dependent lysis CLL targets eightfold augmentation neutrophil ADCC remainder Cytotoxicity expression Confirmation need interaction neutrophil IgG Fc receptors Fc gamma Rs Fc portion MoAb purified Staphylococcus aureus Protein SpA ADCC IFN-gamma exposure consistent alternations expression CLL cells target antigen upregulation unlikely augmentation neutrophil ADCC PBMCs IFN-gamma presence absence IFN-gamma unable CLL targets PBMCs able Raji Burkitt lymphoma cells conjunction ability targets lytic functions intact results importance fresh tumor cells different leukocyte effector subsets clinical trial therapeutic MoAb cytokine 